Goldman Sachs
RAPP

Goldman Sachs’s Rapport Therapeutics RAPP Stock Holding History

Goldman Sachs’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.1M Sell
2,942,251
-59,628
-2% -$1.68M 0.01% 1084
2025
Q4 		$91.1M Buy
3,001,879
+579,903
+24% +$16M 0.01% 1057
2025
Q3 		$71.9M Buy
2,421,976
+1,186,941
+96% +$21.2M 0.01% 1153
2025
Q2 		$14M Sell
1,235,035
-9,275
-0.7% -$98.4K ﹤0.01% 2442
2025
Q1 		$12.5M Sell
1,244,310
-7,826
-0.6% -$102K ﹤0.01% 2477
2024
Q4 		$22.2M Buy
1,252,136
+4,965
+0.4% +$110K ﹤0.01% 2026
2024
Q3 		$25.5M Buy
+1,247,171
New +$26.8M ﹤0.01% 1822

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs's RAPP Position: Q1 2026 in Review

Goldman Sachs reduced its Rapport Therapeutics (RAPP) stake by 2% in Q1 2026, selling an estimated $1.68M and leaving 2,942,251 shares worth $92.1M. The position accounts for 0.01% of the portfolio, ranked #1084.

Goldman Sachs first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Goldman Sachs held 2,942,251 shares of Rapport Therapeutics worth $92.1M as of Q1 2026.
  • Goldman Sachs sold 59,628 Rapport Therapeutics shares in Q1 2026, an estimated $1.68M.
  • Rapport Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1084 holding.
  • Goldman Sachs first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.